BioMarin Pharmaceuticals
BMRN
527 hedge funds and large institutions have $22.3B invested in BioMarin Pharmaceuticals in 2020 Q2 according to their latest regulatory filings, with 88 funds opening new positions, 205 increasing their positions, 166 reducing their positions, and 59 closing their positions.
49% more capital invested
Capital invested by funds: $15B → $22.3B (+$7.38B)
49% more first-time investments, than exits
New positions opened: 88 | Existing positions closed: 59
23% more repeat investments, than reductions
Existing positions increased: 205 | Existing positions reduced: 166
22% more call options, than puts
Call options by funds: $222M | Put options by funds: $182M
5% more funds holding
Funds holding: 500 → 527 (+27)
1.83% more ownership
Funds ownership: 98.49% → 100.31% (+1.8%)
0% more funds holding in top 10
Funds holding in top 10: 11 → 11 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$136M |
| 2 |
N
Nuveen
Charlotte,
North Carolina
|
+$126M |
| 3 |
FAM
Fred Alger Management
New York
|
+$121M |
| 4 |
1832 Asset Management
Toronto,
Ontario, Canada
|
+$93.4M |
| 5 |
PAMU
Pictet Asset Management (UK)
London,
United Kingdom
|
+$68.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Temasek Holdings
Singapore
|
-$200M |
| 2 |
Viking Global Investors
Stamford,
Connecticut
|
-$123M |
| 3 |
Jennison Associates
New York
|
-$62M |
| 4 |
O
OrbiMed
New York
|
-$45.7M |
| 5 |
SC
Samlyn Capital
New York
|
-$44M |
BMRN Hedge Fund Activity: Q2 2020 in Review
527 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in BioMarin Pharmaceuticals (BMRN) for Q2 2020, worth a combined $22.3B — up 49% from $15B a quarter earlier.
Buyers outnumbered sellers: 88 funds opened new BMRN positions and 59 closed out — a net gain of 29 holders — while 205 added to existing stakes and 166 trimmed.
The largest buyer was BlackRock, adding an estimated $136M. The largest seller was Temasek Holdings, exiting entirely with an estimated $200M sold.
- 527 institutional investors held BioMarin Pharmaceuticals (BMRN) as of Q2 2020, up from 500 in Q1 2020.
- Funds reported $22.3B of BioMarin Pharmaceuticals stock for Q2 2020, up 49% quarter-over-quarter.
- 88 funds opened new BioMarin Pharmaceuticals positions in Q2 2020 and 59 closed out, a net change of +29 holders.
- The largest BioMarin Pharmaceuticals buyer in Q2 2020 was BlackRock, an estimated $136M added.
- The largest BioMarin Pharmaceuticals seller in Q2 2020 was Temasek Holdings, an estimated $200M sold.
Based on aggregated 13F filings for Q2 2020.